In the era of precision medicine, cancer diagnosis and treatment are increasingly tailored to the molecular characteristics of individual patients. However, a major barrier to effective personalised therapy is tumour heterogeneity and cellular plasticity, which drive variable treatment responses and the emergence of drug resistance. This challenge is particularly evident in acute myeloid leukaemia (AML), a highly heterogeneous malignancy in which genetically and epigenetically distinct subclones coexist within the same patient and dynamically adapt to therapeutic pressure.
Venetoclax-based regimens have significantly improved outcomes for patients with AML, especially those unfit for intensive chemotherapy. Nevertheless, most patients eventually relapse, and the mechanisms underlying resistance remain poorly understood. Current clinical strategies to enhance venetoclax efficacy are largely empirical, relying on combination therapies without a mechanistic understanding of how tumour cells adapt to targeted treatment. Increasing evidence suggests that non-genetic mechanisms, including epigenetic plasticity and transcriptional adaptation, play a central role in therapy resistance, yet these processes cannot be adequately resolved using bulk sequencing or single-modality approaches.
A key limitation in the field is the inability to simultaneously link genotype, chromatin state, and transcriptional programmes within individual tumour cells in clinical samples. This is particularly problematic in AML, where malignant and pre-leukaemic progenitors often lack distinguishing surface markers, making it difficult to track resistant clones during therapy. As a result, the epigenetic drivers of resistance to targeted therapies, including venetoclax, remain largely unexplored in patients.
The overall objective of this ERC project is to elucidate how epigenetic plasticity contributes to resistance to targeted therapy in AML by integrating longitudinal single-cell multiomics with genotype-resolved analyses in patient samples and experimental models. To address these objectives, the project combines longitudinal single-cell RNA+ATAC multiome profiling, targeted long-read sequencing (scRaCH-seq), and integrative computational analysis in primary AML patient samples, including samples from venetoclax-based clinical trials. In parallel, mechanistic studies in engineered AML cell lines and in vivo models are used to dissect how epigenetic therapies modulate chromatin accessibility, transcriptional programmes, and apoptotic pathways.